drug

golodirsen

1 story · latest Aug 5, 2026

Status: FDA approved Dec 2019 · NDA211970
Brand: Vyondys 53

Relationships

Developed by Sarepta Therapeutics, Inc.

Timeline

Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates

Aug 5Quarterly updateSarepta Therapeutics, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.